Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia

Figures & data

Table 1. Cytogenetic responses at 12 and 18 months after initiation of imatinib and last follow-up for all patients

Cytogenetic response	12 months	18 months	Last follow-up
Complete	4 (10.8%)	5 (13.5%)	5 (13.5%)
Partial	27 (73%)	26 (70.3%)	28 (75.7%)
Minor	5 (13.5%)	3 (8.1%)	4 (10.8%)
Absence	0 (0%)	1 (2.7%)	0 (0%)
NA*	1 (2.7%)	2 (5.4%)	–-

* Patients who did not complete 12- or 18-month follow-up.

Figure 1. Frequency of BCR/ABL transcripts. Three patients were negative for BCR-ABL transcripts because complete molecular response.

Table 2. Demographic characteristics of b3a2 transcript group and other transcript group

Variable		b3a2 transcript	Other transcript	P value
Gender, N (%)	Female	12 (57.1)	6 (37.5)	0.325
	Male	9 (42.9)	10 (62.5)
Age, median (range)		41 (15–68)	40.5 (20–65)	0.712
Hydroxyurea, N (%)	Yes	13 (61.9)	7 (43.8)	0.331
	No	8 (38.1)	9 (56.3)
Months from diagnosis to imatinib start (median)		2	2	0.926
Months of follow-up, median (range)		48 (14–127)	62 (9–131)	0.635
Imatinib dose, median (range) mg		400 (300–600)	400 (300–600)	0.181

Figure 2. Overall survival for both groups.

Table 3. Cytogenetic responses at 12 and 18 months and last follow-up for both groups

	Group	Complete	Partial	Minor	Absence	NA*	P value
12 months	b3a2	3 (14.3%)	15 (71.4%)	3 (14.3%)	0 (0%)	0 (0%)	0.554
	Other	1 (6.3%)	12 (75%)	2 (12.5%)	0 (0%)	1 (6.3%)
18 months	b3a2	4 (19%)	14 (66.7%)	1 (4.8%)	1 (4.8%)	1 (4.8%)	0.476
	Other	1 (6.3%)	12 (75%)	2 (12.5%)	0 (0%)	1 (6.3%)
Last follow-up	b3a2	3 (14.3%)	15 (71.4%)	3 (14.3%)	0 (0%)	—	0.797
	Other	2 (12.5%)	13 (81.3%)	1 (6.3%)	0 (0%)	—

*Patients who did not complete 12- or 18-month follow-up.